SCHEMBL2034442

SCHEMBL2034442

COc1ccc(CNc2cc(NC3CCCN(C(=O)O)C3)nc(-c3cnc4ccc(F)cn34)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GFER P55789 4/20 0.41
CLK1 P49759 1/20 0.41
DYRK1A Q13627 1/20 0.41
GAA P10253 1/20 0.39
MC4R P32245 1/20 0.38
KCNH2 Q12809 1/20 0.38
EGFR P00533 2/20 0.38
ITK Q08881 1/20 0.38
BTK Q06187 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
CCNK O75909 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK7 P50613 1/20 0.37
CCNH P51946 1/20 0.37
MNAT1 P51948 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15194274 0.91 DNMT3A (0.42) RAB9ATDP1GFERCLK1DYRK1A
SCHEMBL15194273 0.91 DNMT3A (0.42) RAB9ATDP1GFERCLK1DYRK1A
SCHEMBL2041813 0.87 JAK2 (0.41) GFEREGFRJAK2JAK1JAK3
SCHEMBL2039977 0.86 JAK2 (0.47) GFEREGFRITKBTKJAK2
SCHEMBL2035314 0.83 JAK2 (0.52) GFEREGFRJAK2JAK1JAK3
SCHEMBL2033799 0.82 FLT3 (0.44) GFERJAK2JAK1JAK3CCNK
SCHEMBL2033048 0.81 EGLN2 (0.40) GFERJAK2JAK1JAK3
SCHEMBL2034765 0.81 ADORA2A (0.41) GFERJAK2JAK1JAK3
SCHEMBL2036766 0.81 JAK2 (0.42) EGFRITKJAK2JAK1JAK3
SCHEMBL16824651 0.80 RAB9A (0.43) RAB9ATDP1GFERGAAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 RAB9A 1909/4885TDP1 2768/4885GFER 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.